AU5741996A - Position-specific integration of vector constructs into eukaryotic genomes mediated by a chimeric integrase protein - Google Patents

Position-specific integration of vector constructs into eukaryotic genomes mediated by a chimeric integrase protein

Info

Publication number
AU5741996A
AU5741996A AU57419/96A AU5741996A AU5741996A AU 5741996 A AU5741996 A AU 5741996A AU 57419/96 A AU57419/96 A AU 57419/96A AU 5741996 A AU5741996 A AU 5741996A AU 5741996 A AU5741996 A AU 5741996A
Authority
AU
Australia
Prior art keywords
mediated
vector constructs
specific integration
eukaryotic genomes
integrase protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU57419/96A
Inventor
Virginia W. Bilanchone
Sandra L. Dildine
Douglas J. Jolly
James G. Respess
Suzanne B. Sandmeyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
University of California
Original Assignee
University of California
Chiron Viagene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, Chiron Viagene Inc filed Critical University of California
Publication of AU5741996A publication Critical patent/AU5741996A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU57419/96A 1995-05-22 1996-05-10 Position-specific integration of vector constructs into eukaryotic genomes mediated by a chimeric integrase protein Abandoned AU5741996A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US445466 1989-12-04
US44546695A 1995-05-22 1995-05-22
PCT/US1996/006727 WO1996037626A1 (en) 1995-05-22 1996-05-10 Position-specific integration of vector constructs into eukaryotic genomes mediated by a chimeric integrase protein

Publications (1)

Publication Number Publication Date
AU5741996A true AU5741996A (en) 1996-12-11

Family

ID=23769021

Family Applications (1)

Application Number Title Priority Date Filing Date
AU57419/96A Abandoned AU5741996A (en) 1995-05-22 1996-05-10 Position-specific integration of vector constructs into eukaryotic genomes mediated by a chimeric integrase protein

Country Status (4)

Country Link
EP (1) EP0830455A1 (en)
JP (1) JPH11505128A (en)
AU (1) AU5741996A (en)
WO (1) WO1996037626A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7332338B2 (en) 1996-10-04 2008-02-19 Lexicon Pharmaceuticals, Inc. Vectors for making genomic modifications
US6139833A (en) * 1997-08-08 2000-10-31 Lexicon Genetics Incorporated Targeted gene discovery
US6855545B1 (en) 1996-10-04 2005-02-15 Lexicon Genetics Inc. Indexed library of cells containing genomic modifications and methods of making and utilizing the same
ATE476508T1 (en) 1997-11-06 2010-08-15 Novartis Vaccines & Diagnostic NEISSERIAL ANTIGENS
EP2210945B1 (en) 1998-01-14 2013-06-26 Novartis Vaccines and Diagnostics S.r.l. Neisseria meningitidis antigens
US6436707B1 (en) 1998-03-27 2002-08-20 Lexicon Genetics Incorporated Vectors for gene mutagenesis and gene discovery
NZ508366A (en) 1998-05-01 2004-03-26 Chiron Corp Neisseria meningitidis antigens and compositions
US7368261B1 (en) 1999-04-30 2008-05-06 Novartis Vaccines And Diagnostics Srl Conserved Neisserial antigens
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
US6936465B1 (en) 1999-06-04 2005-08-30 Nippon Institute For Biological Science Plasmid vector comprising a retroviral integrase gene and an integrase recognition region
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
MXPA02004283A (en) 1999-10-29 2002-10-17 Chiron Spa Neisserial antigenic peptides.
DK1248647T3 (en) 2000-01-17 2010-09-27 Novartis Vaccines & Diagnostic Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins
MXPA03003690A (en) 2000-10-27 2004-05-05 Chiron Spa Nucleic acids and proteins from streptococcus groups a b.
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
NZ562929A (en) 2001-12-12 2009-07-31 Novartis Vaccines & Diagnostic Immunisation against chlamydia trachomatis
ES2358994T3 (en) * 2002-07-24 2011-05-17 Manoa Biosciences Inc. VECTORS BASED ON TRANSPOSONS AND METHODS FOR THE INTEGRATION OF NUCLEIC ACIDS.
US20070059329A1 (en) 2002-11-15 2007-03-15 Nathalie Norais Unexpected surface proteins in meningococcus
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
EP2054431B1 (en) 2006-06-09 2011-08-31 Novartis AG Conformers of bacterial adhesins
EP2669679A1 (en) 2012-05-28 2013-12-04 Universitätsklinikum Hamburg-Eppendorf Method for the detection of glycans using polypeptides comprising the CD301 carbohydrate recognition domain
EP2792742A1 (en) 2013-04-17 2014-10-22 Universitätsklinikum Hamburg-Eppendorf (UKE) Gene-therapy vectors for treating cardiomyopathy
CN104975353A (en) * 2015-06-08 2015-10-14 浙江大学 Construction method of HIV-1 integrase mutant library

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005787A1 (en) * 1988-11-23 1990-05-31 The Regents Of The University Of California Position-specific insertion vectors and method of using same
WO1991002805A2 (en) * 1989-08-18 1991-03-07 Viagene, Inc. Recombinant retroviruses delivering vector constructs to target cells
FR2670502B1 (en) * 1990-12-13 1994-09-16 Eurolysine "MULTISITE" INTEGRATION CASSETTE IN THE GENOME OF A YEAST, PROCESSED YEAST AND PROCESS FOR THE PREPARATION OF A PRODUCT OF INTEREST BY A YEAST THUS PROCESSED.
JP3449418B2 (en) * 1991-05-31 2003-09-22 ジェネンテック・インコーポレーテッド Increased expression by gene targeting into endogenous retrovirus-like sequences
US5252479A (en) * 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
AU4401993A (en) * 1992-06-04 1993-12-30 Exemplar Corporation Insertion of heterologous dna outside of known chromosomal genes
JPH09508017A (en) * 1994-01-12 1997-08-19 ジェネティック セラピー，インコーポレイテッド Purification of retrovirus vector

Also Published As

Publication number Publication date
WO1996037626A1 (en) 1996-11-28
EP0830455A1 (en) 1998-03-25
JPH11505128A (en) 1999-05-18

Similar Documents

Publication Publication Date Title
AU5741996A (en) Position-specific integration of vector constructs into eukaryotic genomes mediated by a chimeric integrase protein
AU6625296A (en) Dna constructs
AU4344093A (en) Preparation of nucleic acids
NZ313108A (en) Papillomavirus polyprotein constructs
AU5511998A (en) Ultrasonic forming of confectionery products
AU7351591A (en) Seroreactive epitopes of human papillomavirus (HPV) 16 proteins
AU4209197A (en) Process for the control of weeds
AU3199595A (en) Ubiquitin-lytic peptide fusion gene constructs, protein products deriving therefrom, and methods of making and using same
AU7317496A (en) Activation of p53 protein
AU699020B2 (en) Liquid formulations of 1,2-benzisothiazolin-3-one
AU5134599A (en) Expression of functional eukaryotic proteins
AU1406497A (en) Mutational variants of mammalian ob gene proteins
AU3897093A (en) Papillomavirus E7 protein
AU5602394A (en) Chimeric blood coagulation proteins
AU4479096A (en) 5-methanesulfonamido-3h-isobenzofuran-1-ones as inhibitors of cyclooxygenase-2
AU2467395A (en) Novel ophthalmologic uses of protein c
AU7136196A (en) Pharmaceutical composition which is useful for the transfection of nucleic acids, and uses thereof
AU677538B2 (en) Soil fumigant preparations
AU5652396A (en) Glucose-inducible recombinant viral vector
AU7169196A (en) Distillation of vinylaromatic monomer
AU3958895A (en) Membrane expression of heterologous genes
AU4489196A (en) Novel medical use of heme products
AU1106297A (en) Genetic control of fruit ripening
AU6097896A (en) Oral delivery of gene constructs
AU5676096A (en) Chimeric nucleic acids and proteins for inhibiting hiv-1 exp ression